为治理招投标乱象，最高人民法院、国家发展改革委联合发布6件人民法院审结的串通投标及其关联犯 罪典型案例。两部门组织指导各地、各有关方面协同整治招投标领域突出问题，依法严惩串通投标及其 关联犯罪，严厉打击以非法手段排除、限制竞争的行为。 ...

重庆三峡学院的设备采购风波还在发酵。日前，网曝重庆三峡学院在进行设备采购时疑似存在违规行 为。该校采购的"防火墙及DNS设备"，中标价格为85万元，其中一台"普联TL-R473G出口防火墙"单价 为75万元，而其实该产品只是一台路由器，电商平台定价299元。5月11日，涉事学院回应称已终止采 购。目前，重庆市教委、纪委、财政局已介入调查。 通过正规的招投标程序，用75万元买只要299元的路由器，如此离谱之事经由媒体、网友深度挖掘，更 多细节得以一一披露。因为信息公开推动的招投标领域个案调查，也算是一种及时止损。问题在于，已 经到了中标结果公告阶段的这个肉到嘴边的单子，究竟是如何通过招标、投标、开标、评标、中标这一 系列法定的招投标程序的？ 2024年5月，国务院办公厅下发《关于创新完善体制机制推动招标投标市场规范健康发展的意见》，明 确要求加强评标专家全周期管理，加快实现评标专家资源跨地区跨行业共享，包括广东等多地都已出台 落实文件，鼓励招标人不限评标专家常驻地、意向评标地随机从省综合评标评审专家库抽取评标专家， 以打破本地评标专家"小圈子"。对照此番重庆三峡学院的招投标个案可以看到，涉事的多名评标专家依 然 ...

Core Viewpoint - In 2024, the company faced performance pressure due to delays in medical equipment bidding, but a market recovery in Q1 2025 led to a year-on-year performance rebound [1][2]. Financial Performance - In 2024, the company achieved revenue of 10.3 billion yuan (-9.73%) and a net profit attributable to shareholders of 1.262 billion yuan (-36.08%) [1]. - Q4 2024 revenue was 3.346 billion yuan (-15.90%), with a net profit of 591 million yuan (-35.09%) [1]. - Q1 2025 revenue increased to 2.478 billion yuan (+5.42%), with a net profit of 370 million yuan (+1.87%) [1]. Product Line Analysis - In 2024, equipment sales revenue was 8.445 billion yuan (-14.9%), with specific product line revenues showing varied performance: CT/MR/MI/XR/RT products down by 25%/-3%/-16%/-23% but RT business grew by 18% [1]. - The maintenance service business grew rapidly, achieving revenue of 1.356 billion yuan (+26.8%) due to increased installed capacity [1]. Market Performance - Domestic market revenue in 2024 was 7.66 billion yuan (-21.3%), impacted by industry restructuring and prolonged equipment update policies [2]. - Overseas market revenue reached 2.22 billion yuan (+32.3%), with its revenue share increasing to 21.6% (+6.9 percentage points) due to technological innovation and product diversification [2]. Profitability and Expenses - The company's gross margin in 2024 was 48.54% (+0.06 percentage points), remaining stable [2]. - Expense ratios increased: sales expense ratio at 17.70% (+2.19 percentage points), management expense ratio at 5.40% (+0.48 percentage points), R&D expense ratio at 17.10% (+1.95 percentage points) [2]. Investment Outlook - The domestic bidding recovery is expected to drive performance recovery, with a significant impact from the global strategy [3]. - Revised revenue forecasts for 2025-2027 are 12.04 billion yuan, 13.77 billion yuan, and 15.53 billion yuan, with corresponding net profits of 1.70 billion yuan, 2.08 billion yuan, and 2.33 billion yuan [3].